MSD

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

PENDULUM® Announces the Branding of its Strategic Advisory Services with the Launch of Pendulum Sports & Entertainment

Retrieved on: 
Thursday, March 14, 2024
Content Marketing, General Sports, Sports, Entertainment, Consulting, Advertising, Communications, Professional Services, General Entertainment, MSD, EPL, Negotiation, Culture, Sport, BDT, Partnership, Branding, LLP, Athlete, MLS, NWSL, MLB, Ecosystem, Partner, Holding, NBA, Family, Reinforcement learning

Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.

Key Points: 
  • Pendulum Holdings, LLC (“Pendulum”), a strategic investment and advisory platform, today announced the launch of Pendulum Sports & Entertainment LLC (“PSE”), a dedicated team of senior professionals within Pendulum that provides trusted, strategic advisory services to a formidable generation of brand owners building businesses and partnerships that move and lead culture.
  • PSE serves as a transformative bridge between its clients’ brands and their most significant business ambitions and endeavors.
  • Founded in 2019 by D’Rita and Robbie Robinson, Pendulum seeks to reimagine how great companies are built and redefine who gets to build them.
  • “The launch of PSE demonstrates continued momentum in our business and is a significant milestone for Pendulum.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, FDA, Diabetes, Health, Legal, Pharmaceutical, Professional Services, Oncology, Other Science, Research, Infectious Diseases, General Health, Genetics, Science, MSD, Entrepreneurship, Yale University, Partnership, Synthetic biology, Epitope, Khosla Ventures, Pearl, Merck & Co., Merck, GRO, Cancer, Stanford University, Scottish Register of Tartans, Pharmaceutical industry

Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Key Points: 
  • Pearl Bio (a synthetic biology company backed by Khosla Ventures) today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.
  • "Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries,” shared Juan Alvarez, Vice President of Discovery Biologics at Merck Research Laboratories.
  • Backed by Khosla Ventures, Pearl Bio was launched by Scientific Co-Founders Drs.
  • (Pearl Bio) bringing together an exclusive platform technology to advance multi-functionalized biologics and biomaterials by encoding synthetic chemistries.

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Retrieved on: 
Monday, March 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, Glomus tumor, Carcinoma, EPS, BCMA, Patient, Neoplasm, Merck & Co., Acquisition, Cancer, Epithelial cell adhesion molecule, DLL3, MRK, Safety, Pharmacokinetics, B-cell maturation antigen, SCLC, Food, Pharmaceutical industry

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).
  • Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.
  • “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories.
  • Under the terms of the merger agreement, Merck, through a subsidiary, has acquired all outstanding shares of Harpoon.

American College of Education Presents Four Full Scholarships in Partnership With Indiana Association of Public Education Foundation

Retrieved on: 
Wednesday, March 27, 2024
MSD, Tippecanoe School Corporation, Partnership, Education, Lake Central School Corporation, Organization, American College, ACE

INDIANAPOLIS, March 27, 2024 /PRNewswire/ -- American College of EducationⓇ (ACE) has announced a partnership with the Indiana Association of Public Education Foundation (INAPEF) to award full tuition scholarships to four education professionals in Indiana representing the MSD of Wayne Township, Tippecanoe School Corporation, Center Grove Community School Corporation and Lake Central School Corporation. The recipients will receive what amounts to $25K worth of scholarship funding for the 2023-24 school year.

Key Points: 
  • INDIANAPOLIS, March 27, 2024 /PRNewswire/ -- American College of EducationⓇ ( ACE ) has announced a partnership with the Indiana Association of Public Education Foundation (INAPEF) to award full tuition scholarships to four education professionals in Indiana representing the MSD of Wayne Township, Tippecanoe School Corporation, Center Grove Community School Corporation and Lake Central School Corporation.
  • The recipients will receive what amounts to $25K worth of scholarship funding for the 2023-24 school year.
  • Both organizations aim to use the scholarships to support INAPEF member organizations and ACE's mission of providing access to affordable, flexible and high-quality education.
  • "This collaboration is a great way to support educator development in Indiana," INAPEF Association Administrator Krista Baber added.

Josh Harris & David Blitzer Launch Unrivaled Sports And Take Significant, Strategic Investment From The Chernin Group

Retrieved on: 
Wednesday, March 27, 2024
MSD, Friends, Nike (company), Peter Chernin, Sport, Learning, BDT, Philosophy, Partnership, Baseball, SpringHill Company, TCG (company), Growth, Athlete, Blitzer, Campion, LA28, Real Salt Lake, Investment, Baseball Factory, Paralympic Games, TCG, Family, UCLA, Olympic Gold, Hall

NEW YORK, March 27, 2024 /PRNewswire/ -- Josh Harris and David Blitzer announced today the formation of Unrivaled Sports, the new parent company for their growing portfolio of youth sports properties. As part of the announcement, The Chernin Group ("TCG"), a multi-stage investment firm dedicated to building consumer businesses, completed a significant strategic investment in Unrivaled Sports. Andy Campion, former Chief Operating Officer of Nike, Inc. and long-time Disney executive, has been named Unrivaled Sports' Chairman of the Board. Through its 12 owned and operated facilities, Unrivaled Sports welcomes more than 550,000 athletes and 1.1 million attendees annually.

Key Points: 
  • As part of the announcement, The Chernin Group ("TCG"), a multi-stage investment firm dedicated to building consumer businesses, completed a significant strategic investment in Unrivaled Sports.
  • Andy Campion, former Chief Operating Officer of Nike, Inc. and long-time Disney executive, has been named Unrivaled Sports' Chairman of the Board.
  • Through its 12 owned and operated facilities, Unrivaled Sports welcomes more than 550,000 athletes and 1.1 million attendees annually.
  • "Through Unrivaled Sports, we're not just investing in sports; we're investing in future generations by making sports more inclusive and accessible in communities across the nation," Harris said.

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

Retrieved on: 
Friday, March 15, 2024
MSD, Health, Growth, Pig, Merck, Behavior, MRK, Schering-Plough, HOD, Merck & Co., Animal, Artificial intelligence

HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).  MSD Animal Health, a biopharmaceuticals and technology solutions company, has participated in FarmSee's A round and has entered into a long-term agreement to integrate FarmSee's AI- based weighing technology into its global offerings for swine producers. FarmSee also has partnered with Munters (STO:MTRS) in their A round funding.

Key Points: 
  • FarmSee also has partnered with Munters (STO:MTRS) in their A round funding.
  • FarmSee's Initial focus is on continuous individual weight monitoring, which is critical for tracking the animals' growth pattern.
  • "This collaboration not only validates the value of our technology but also opens new opportunities for growth and expansion for FarmSee.
  • We look forward to the growth and development of FarmSee's swine-monitoring technology, which will integrate into our suite of identification, monitoring and traceability animal health solutions.

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Retrieved on: 
Tuesday, March 12, 2024
MSD, PARG, Apoptosis, Prostate cancer, Endometrial cancer, Colorectal cancer, RECIST, Patient, MSI, Merck & Co., Pembrolizumab, Medicine, MSS, Breast cancer, HRD, Therapy, ADP, PD-1, Pharmaceutical industry

"We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.

Key Points: 
  • "We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.
  • "We are very pleased to collaborate with Merck on this trial evaluating IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer.
  • Under the clinical trial collaboration and supply agreement, Merck will provide KEYTRUDA to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial.
  • The mechanistic rationale and preclinical data to support the IDE161 and PD-1 clinical combination will be provided as part of a future R&D update.

NOBLIS MSD NAMES JIM BROADWATER AS VICE PRESIDENT OF ITS NAVSEA DIVISION

Retrieved on: 
Tuesday, March 5, 2024
MSD, Naval Sea Systems Command, Sigma, Risk management, United States Navy, Noblis, University, Information technology, Navy, Science, Partnership, Management

Reston, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today named Jim Broadwater as vice president of its Naval Sea Systems Command (NAVSEA) division.

Key Points: 
  • Reston, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today named Jim Broadwater as vice president of its Naval Sea Systems Command (NAVSEA) division.
  • Reporting to Glenn Hickok , Noblis MSD president, Broadwater will expand the company’s NAVSEA strategy to bring additional digital engineering and breakthrough technologies to its U.S. Navy partners.
  • “Jim has deep domain knowledge and an unwavering commitment to innovation, operational excellence and fiscal responsibility,” said Hickok.
  • “Under his leadership, Noblis has delivered high-value transformational solutions and rapid prototypes that help our U.S. Navy partners advance mission readiness and competitive advantage.